Free Trial
NASDAQ:ATRA

Atara Biotherapeutics (ATRA) Stock Price, News & Analysis

Atara Biotherapeutics logo
$9.48 +0.25 (+2.71%)
Closing price 04:00 PM Eastern
Extended Trading
$9.46 -0.02 (-0.21%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Atara Biotherapeutics Stock (NASDAQ:ATRA)

Key Stats

Today's Range
$9.25
$9.60
50-Day Range
$6.47
$9.27
52-Week Range
$5.01
$18.71
Volume
35,112 shs
Average Volume
117,370 shs
Market Capitalization
$56.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.75
Consensus Rating
Moderate Buy

Company Overview

Atara Biotherapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
82nd Percentile Overall Score

ATRA MarketRank™: 

Atara Biotherapeutics scored higher than 82% of companies evaluated by MarketBeat, and ranked 182nd out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Atara Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 3 buy ratings, 2 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Atara Biotherapeutics has received no research coverage in the past 90 days.

  • Read more about Atara Biotherapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Atara Biotherapeutics are expected to grow in the coming year, from ($10.39) to ($10.04) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Atara Biotherapeutics is -2.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Atara Biotherapeutics is -2.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Atara Biotherapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    8.63% of the float of Atara Biotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Atara Biotherapeutics has a short interest ratio ("days to cover") of 5.
  • Change versus previous month

    Short interest in Atara Biotherapeutics has recently decreased by 22.21%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Atara Biotherapeutics does not currently pay a dividend.

  • Dividend Growth

    Atara Biotherapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.63% of the float of Atara Biotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Atara Biotherapeutics has a short interest ratio ("days to cover") of 5.
  • Change versus previous month

    Short interest in Atara Biotherapeutics has recently decreased by 22.21%, indicating that investor sentiment is improving significantly.
  • Search Interest

    Only 1 people have searched for ATRA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Atara Biotherapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Atara Biotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $37,139.00 in company stock.

  • Percentage Held by Insiders

    Only 4.00% of the stock of Atara Biotherapeutics is held by insiders.

  • Percentage Held by Institutions

    70.90% of the stock of Atara Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Atara Biotherapeutics' insider trading history.
Receive ATRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atara Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATRA Stock News Headlines

Atara Biotherapeutics, Inc. (ATRA) - Yahoo Finance
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
See More Headlines

ATRA Stock Analysis - Frequently Asked Questions

Atara Biotherapeutics' stock was trading at $13.31 at the start of the year. Since then, ATRA shares have decreased by 29.0% and is now trading at $9.45.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) announced its earnings results on Thursday, May, 15th. The biotechnology company reported $3.50 earnings per share for the quarter, topping analysts' consensus estimates of ($3.07) by $6.57. The biotechnology company earned $98.10 million during the quarter, compared to the consensus estimate of $4.30 million.

Atara Biotherapeutics shares reverse split on Thursday, June 20th 2024.The 1-25 reverse split was announced on Thursday, June 20th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Shares of ATRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Atara Biotherapeutics investors own include Agenus (AGEN), CRISPR Therapeutics (CRSP), Pfizer (PFE), Athersys (ATHX), Advanced Micro Devices (AMD), Bristol Myers Squibb (BMY) and FuelCell Energy (FCEL).

Company Calendar

Last Earnings
5/15/2025
Today
7/10/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ATRA
CIK
1604464
Fax
N/A
Employees
330
Year Founded
N/A

Price Target and Rating

High Price Target
$25.00
Low Price Target
$11.00
Potential Upside/Downside
+87.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.72)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$85.40 million
Net Margins
-7.83%
Pretax Margin
-7.85%
Return on Equity
N/A
Return on Assets
-14.51%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.57
Quick Ratio
0.57

Sales & Book Value

Annual Sales
$128.94 million
Price / Sales
0.44
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($16.89) per share
Price / Book
-0.56

Miscellaneous

Outstanding Shares
5,960,000
Free Float
5,723,000
Market Cap
$56.50 million
Optionable
Optionable
Beta
0.18

Social Links

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:ATRA) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners